1607485-96-0Relevant articles and documents
Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model
Pero, Joseph E.,Rossi, Michael A.,Lehman, Hannah D.G.F.,Kelly, Michael J.,Mulhearn, James J.,Wolkenberg, Scott E.,Cato, Matthew J.,Clements, Michelle K.,Daley, Christopher J.,Filzen, Tracey,Finger, Eleftheria N.,Gregan, Yun,Henze, Darrell A.,Jovanovska, Aneta,Klein, Rebecca,Kraus, Richard L.,Li, Yuxing,Liang, Annie,Majercak, John M.,Panigel, Jacqueline,Urban, Mark O.,Wang, Jixin,Wang, Ying-Hong,Houghton, Andrea K.,Layton, Mark E.
, p. 2683 - 2688 (2017/05/29)
Studies on human genetics have suggested that inhibitors of the Nav1.7 voltage-gated sodium channel hold considerable promise as therapies for the treatment of chronic pain syndromes. Herein, we report novel, peripherally-restricted benzoxazoli
